查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1877452

CAR-T细胞疗法市场：依产品类型、标靶抗原、适应症、最终用户、国家及地区划分－全球产业分析、市场规模、市场占有率及2025-2032年预测

CAR T-cell Therapy Market, By Product Type, By Target Antigen, By Indication, By End user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 365 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年 CAR T 细胞疗法市场规模价值为 56.78 亿美元，从 2025 年到 2032 年将以 38.5% 的复合年增长率成长。

CAR-T细胞疗法是一种利用基因工程改造的免疫细胞疗法，它能修饰患者自身的T细胞，使其标靶并杀死癌细胞。该疗法最初用于治疗某些血液癌症，目前也越来越多地探索其在实体肿瘤治疗中的应用。由于在復发或难治性血液系统恶性肿瘤中取得了显着的临床疗效，加上研发管线的拓展、监管审批的增加以及生物製药和特种细胞疗法生产商投资的不断增长，CAR-T细胞疗法市场正迅速扩张。复杂的生产流程、对专业治疗中心的需求以及高昂的治疗费用构成了一定的挑战，但生产规模的扩大、合作伙伴关係的建立以及新一代CAR-T细胞的设计正在推动其商业化进程。

CAR-T细胞疗法市场－市场动态

临床疗效提高，缓解期持久

CAR-T细胞疗法显着提高了復发或难治性血液肿瘤患者的临床疗效，并实现了持久缓解。临床试验和真实世界应用的大量结果表明，该疗法能够在其他疗法失败的情况下产生长期疗效，这促使医生采用该疗法，促使支付方承担高昂的费用，并吸引了渴望拓展适应症和扩大生产规模的製药公司和製造商的投资。

CAR-T细胞疗法市场区隔分析：

全球 CAR T 细胞疗法市场按产品类型、目标抗原、适应症、最终用户和地区进行细分。

根据产品类型，市场分为七大类：Abecma、Breyanzi、Carvykti、Kymriah、Tecartus、Yescarta 和其他。目前，Kymriah 和 Yescarta 等成熟产品凭藉其更早累积的更广泛的临床经验、已获批准的药品以及更大的商业覆盖面，占据市场主导地位。

标靶抗原市场又可细分为七类：CD19、BCMA（B细胞成熟抗原）、CD22、GD2、HER2、GPC3 和其他（例如 EGFRvIII、CD7、CD123、间皮素）。 CD19 目前仍是该领域的主导类别，这主要得益于其在 B 细胞白血病和淋巴瘤治疗中取得的成功。 BCMA 是成长最快的类别，这主要归功于其在多发性骨髓瘤治疗中的显着疗效以及不断涌现的新产品。

依适应症划分，共有四大类：急性淋巴性白血病、淋巴瘤、多发性骨髓瘤及套细胞淋巴瘤。由于多种BCMA CAR-T疗法即将上市，多发性骨髓瘤在短期内最具成长潜力。实体瘤是最大的长期发展机会，但面临巨大的科学和转化障碍，将延缓其商业化。血液系统恶性肿瘤（急性淋巴性白血病、各种淋巴瘤和多发性骨髓瘤）将继续推动近期收入和市场普及，因为大多数核准药物和临床经验都集中在这一领域。

最终使用者群体包括医院和专门的癌症治疗中心，这些是主要的治疗场所，因为 CAR-T 疗法需要专门的基础设施、住院监测和多学科团队；这些中心将占据当前的大部分业务量。

CAR-T细胞疗法市场—地域性洞察

北美，尤其是美国，是最大的市场，这得益于强劲的生物技术投资、完善的临床试验基础设施和有利的报销政策；欧洲紧随其后，采用率不断提高，但各国的报销情况不尽相同；亚太地区是一个高增长地区，这得益于医疗保健支出的增长、中国、日本和韩国临床能力的发展以及一些国家製造的价格

CAR-T细胞疗法市场－竞争格局：

竞争格局由拥有已批准的 CAR-T 产品的大型生物技术/製药公司和众多开发下一代和同种异体疗法的小型创新者和学术衍生公司主导；竞争的重点是临床表现、安全性（减少细胞因子释放综合征/神经毒性）、生产规模和成本以及生产和分销的商业合作关係，併购、许可协议和战略联盟很常见，因为公司正在努力确保产品线。

目录

第一章：CAR-T细胞疗法市场概览

  • 研究范围
  • 市场估算年份

第二章：执行概要

  • 市集
    • CAR T 细胞疗法市场按产品类型分類的概览
    • CAR T 细胞疗法市场概览（以标靶抗原划分）
    • CAR-T细胞疗法市场按适应症分類的概况
    • CAR T 细胞疗法市场按最终用户分類的概览
    • 各国 CAR-T 细胞疗法市场概况
    • CAR-T细胞疗法市场概览（按地区划分）
  • 竞争洞察

第三章：CAR-T细胞疗法主要市场趋势

  • CAR-T细胞疗法市场驱动因素
    • 市场驱动因素的影响分析
  • CAR-T细胞疗法市场限制因素
    • 市场限制因素的影响分析
  • CAR-T细胞疗法市场机会
  • CAR-T细胞疗法市场未来趋势

第四章：CAR-T细胞疗法产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 规范架构分析

第五章：CAR-T细胞疗法市场：地缘政治紧张局势升级的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：CAR-T细胞疗法市场概况

  • CAR-T细胞疗法市占率分析，2024年
  • 主要製造商细分数据
    • 知名球员分析
    • 新兴参与者分析

第七章：CAR-T细胞疗法市场－依产品类型划分

  • 概述
    • 按产品类型分類的细分市场占有率分析
    • 阿贝克玛
    • 布雷扬齐
    • 卡维克蒂
    • 凯姆里亚
    • 泰卡图斯
    • 耶斯卡塔
    • 其他的

第八章：CAR-T细胞疗法市场－以标靶抗原划分

  • 概述
    • 按标靶抗原分類的细分市场份额分析
    • CD19
    • BCMA（B细胞成熟抗原）
    • CD22
    • GD2
    • HER2
    • GPC3
    • 其他（例如，EGFRvIII、CD7、CD123、间皮素）

第九章：CAR-T细胞疗法市场－依适应症划分

  • 概述
    • 按指标分類的细分市场占有率分析
    • 急性淋巴性白血病
    • 淋巴瘤
    • 多发骨髓瘤
    • 套细胞淋巴瘤

第十章：CAR-T细胞疗法市场－以最终用户划分

  • 概述
    • 按标靶抗原分類的细分市场份额分析
    • 医院
    • 癌症治疗中心
    • 其他的

第十一章：CAR-T细胞疗法市场－依地域划分

  • 介绍
    • 按地域分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美CAR-T细胞疗法主要生产商
    • 北美市场规模及预测（按国家/地区划分）
    • 北美市场规模及预测（依产品类型划分）
    • 北美市场规模及预测（以标靶抗原划分）
    • 北美市场规模及预测（依适应症划分）
    • 北美市场规模及预测（依最终用户划分）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲CAR-T细胞疗法主要生产商
    • 欧洲市场规模及预测（按国家/地区划分）
    • 欧洲市场规模及预测（依产品类型划分）
    • 欧洲市场规模及预测（以标靶抗原划分）
    • 欧洲市场规模及预测（依适应症划分）
    • 欧洲市场规模及预测（依最终用户划分）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区
    • 概述
    • 亚太地区CAR T细胞疗法主要生产商
    • 亚太市场规模及预测（依国家/地区划分）
    • 亚太市场规模及预测（依产品类型划分）
    • 亚太市场规模及预测（以标靶抗原划分）
    • 亚太地区市场规模及预测（依适应症划分）
    • 亚太市场规模及预测（依最终用户划分）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲CAR T细胞疗法主要生产商
    • 拉丁美洲市场规模及预测（按国家/地区划分）
    • 拉丁美洲市场规模及预测（依产品类型划分）
    • 拉丁美洲市场规模及预测（以标靶抗原划分）
    • 拉丁美洲市场规模及预测（依适应症划分）
    • 拉丁美洲市场规模及预测（按最终用户划分）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲CAR T细胞疗法主要生产商
    • MEA市场规模及预测（依国家/地区划分）
    • MEA市场规模及预测（依产品类型划分）
    • MEA市场规模及预测（以标靶抗原划分）
    • MEA市场规模及预测（依适应症划分）
    • MEA市场规模及预测（依最终用户划分）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 中东和非洲其他地区

第十二章：主要供应商分析－CAR-T细胞疗法产业

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • XX
    • Others

第十三章：360度AnalystView

第十四章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5762

CAR T-cell Therapy Market size was valued at US$ 5,678 Million in 2024, expanding at a CAGR of 38.5% from 2025 to 2032.

The CAR T-cell therapy involves engineered immune cell treatments that modify a patient's T cells which targets and then kills cancer cells, Specifically for certain blood cancers and is increasingly explored for solid tumors. The market is rapidly expanding due to robust clinical outcomes in relapsed or refractory hematologic malignancies, expanded research pipelines, increasing regulatory approvals, and increasing investment from biopharma and specialty cell therapy manufacturers. Complex manufacturing, the need for specialized treatment centers and High treatment costs, pose challenges, but manufacturing scale-up, partnerships and next-generation CAR designs are helping commercial expansion.

CAR T-cell Therapy Market- Market Dynamics

Improved Clinical Efficacy and Durable Remissions

CAR Tcell therapy has improved clinical efficacy and lasting remissions in patients with relapsed or refractory blood cancers. Strong results from clinical trials and real-world use have shown the treatment can produce long-term responses where other therapies failed, which encourages doctors to adopt it, motivates payers to cover the high costs, and attracts investment from pharmaceutical companies and manufacturers eager to expand indications and scale production.

CAR T-cell Therapy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 38.5% over the forecast period (2025-2032)

Based on product type segmentation, Kymriah was predicted to show maximum market share in the year 2024

Based on target antigen segmentation, CD19 was the leading target antigen in 2024

Based on Indication segmentation, acute lymphoblastic leukemia was the leading indication segment in 2024

Based on end user segmentation, Cancer treatment centres was the leading indication segment in 2024

On the basis of region, North America was the leading revenue generator in 2024

CAR T-cell Therapy Market- Segmentation Analysis:

The Global CAR T-cell Therapy Market is segmented on the basis of Product Type, Target Antigen, Indication, End user, and Region.

The market is divided into seven categories based on product type: Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta and Others. The Established products like Kymriah and Yescarta lead the market at present because of earlier broader clinical experience, approvals, and larger commercial footprints.

For the Target Antigen the market is divided into again seven categories: CD19, BCMA (B-cell Maturation Antigen), CD22, GD2, HER2, GPC3 and Others (e.g., EGFRvIII, CD7, CD123, mesothelin). CD19 remains the dominant category in this segment today, driven by established success in B-cell leukemias and lymphomas. BCMA is the fastest growing category due to the strong responses in multiple myeloma and increasing product launches.

In By Indication segment there are four categories: Acute lymphoblastic leukemia, Lymphoma, Multiple Myeloma and Mantle Cell Lymphoma. Multiple myeloma represents the highest near-term upside due to multiple BCMA CARs entering the market. Solid tumors are the largest long-term opportunity but face substantial scientific and translational hurdles that will slow commercialization. Hematologic malignancies (acute lymphoblastic leukemia, various lymphomas, and multiple myeloma) will continue to drive near-term revenue and adoption because most approvals and clinician experience are concentrated here.

The End User segments includes Hospitals and specialized cancer treatment centers these are the primary sites of care because CAR T therapies need specialized infrastructure, inpatient monitoring, and multidisciplinary teams; these centers will capture the majority of current volume.

CAR T-cell Therapy Market- Geographical Insights

North America, particularly the United States, is the largest market due to strong biotech investment, established clinical trial infrastructure, and favorable reimbursement policies; Europe follows with growing adoption but variable national reimbursement landscapes; Asia-Pacific is a high-growth region driven by rising healthcare spending, expanding clinical capabilities in China, Japan, and South Korea, and increasing local manufacturing, though access and pricing remain barriers in some countries.

CAR T-cell Therapy Market- Competitive Landscape:

The competitive landscape is led by a mix of large biotech/pharma companies with approved CAR T products and numerous smaller innovators and academic spinouts developing next-generation and allogeneic therapies; competition centers on clinical performance, safety (reduced cytokine release syndrome/neurotoxicity), manufacturing scale and cost, and commercial partnerships for manufacturing and distribution, with M&A, licensing deals, and strategic alliances common as companies move to secure pipelines and production capacity.

Recent Developments:

On November 5, 2025, Prime Minister Narendra Modi unveiled three Indian innovations at ESTIC2025: QSIP, a 25-qubit QPU, and NexCAR19 - India's first indigenous CAR-T therapy by ImmunoACT. DBT and BIRAC supported development and funded a 200L GMP lentiviral production platform expected to serve about 1,000 patients a year. Ongoing DBT/BIRAC funding also supports wider CAR-T research for blood and solid tumors.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CAR T-CELL THERAPY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • ALLOGENE THERAPEUTICS
  • Aurora Biopharma
  • Bristol-Myers Squibb company
  • Cartesian Therapeutics, Inc.
  • Curocell Inc
  • Gilead Sciences
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics
  • Lonza
  • Novartis
  • Others

GLOBAL CAR T-CELL THERAPY MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Abecma
  • Breyanzi
  • Carvykti
  • Kymriah
  • Tecartus
  • Yescarta
  • Others

GLOBAL CAR T-CELL THERAPY MARKET, BY TARGET ANTIGEN- MARKET ANALYSIS, 2019 - 2032

  • CD19
  • BCMA (B-cell Maturation Antigen)
  • CD22
  • GD2
  • HER2
  • GPC3
  • Others (e.g., EGFRvIII, CD7, CD123, mesothelin)

GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Acute lymphoblastic leukemia
  • Lymphoma
  • Multiple Myeloma
  • Mantle Cell Lymphoma

GLOBAL CAR T-CELL THERAPY MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Treatment Centers
  • Others

GLOBAL CAR T-CELL THERAPY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. CAR T-cell Therapy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. CAR T-cell Therapy Market Snippet by Product Type
    • 2.1.2. CAR T-cell Therapy Market Snippet by Target Antigen
    • 2.1.3. CAR T-cell Therapy Market Snippet by Indication
    • 2.1.4. CAR T-cell Therapy Market Snippet by End user
    • 2.1.5. CAR T-cell Therapy Market Snippet by Country
    • 2.1.6. CAR T-cell Therapy Market Snippet by Region
  • 2.2. Competitive Insights

3. CAR T-cell Therapy Key Market Trends

  • 3.1. CAR T-cell Therapy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. CAR T-cell Therapy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. CAR T-cell Therapy Market Opportunities
  • 3.4. CAR T-cell Therapy Market Future Trends

4. CAR T-cell Therapy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. CAR T-cell Therapy Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. CAR T-cell Therapy Market Landscape

  • 6.1. CAR T-cell Therapy Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. CAR T-cell Therapy Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Abecma
    • 7.1.3. Breyanzi
    • 7.1.4. Carvykti
    • 7.1.5. Kymriah
    • 7.1.6. Tecartus
    • 7.1.7. Yescarta
    • 7.1.8. Others

8. CAR T-cell Therapy Market - By Target Antigen

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Target Antigen, 2024 & 2032 (%)
    • 8.1.2. CD19
    • 8.1.3. BCMA (B-cell Maturation Antigen)
    • 8.1.4. CD22
    • 8.1.5. GD2
    • 8.1.6. HER2
    • 8.1.7. GPC3
    • 8.1.8. Others (e.g., EGFRvIII, CD7, CD123, mesothelin)

9. CAR T-cell Therapy Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 9.1.2. Acute lymphoblastic leukemia
    • 9.1.3. Lymphoma
    • 9.1.4. Multiple Myeloma
    • 9.1.5. Mantle Cell Lymphoma

10. CAR T-cell Therapy Market - By End user

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Target Antigen, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Cancer Treatment Centers
    • 10.1.4. Others

11. CAR T-cell Therapy Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. CAR T-cell Therapy Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. CAR T-cell Therapy Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. CAR T-cell Therapy Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. CAR T-cell Therapy Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. CAR T-cell Therapy Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- CAR T-cell Therapy Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. XX
    • 12.2.2. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us